PDCD1 and metastatic melanoma: In the phase III CheckMate 067 trial [6], 945 therapy-naive patients with metastatic melanoma received the anti-PD-1 antibody nivolumab in combination with the anti-CTLA-4 antibody ipilimumab or nivolumab, or ipilimumab as monotherapy.